This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stasch, J. P. Articles by Morich, F. Search for Related Content PubMed PubMed Citation Articles by Stasch, J. P. Articles by Morich, F.

Hypertension, Vol 10, 303-307, Copyright © 1987 by American Heart Association

ARTICLES

Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive rats

JP Stasch, S Kazda, C Hirth and F Morich

The effect of long-term treatment with the calcium antagonist nisoldipine on development of hypertension, cardiac hypertrophy, and plasma levels of atrial natriuretic peptides (ANP) was determined in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) of the same age. Measurement of immunoreactive ANP in plasma provided a sensitive marker for the severity of hypertension and the associated cardiac overload. Long-term treatment with nisoldipine prevented the development of hypertension, the associated heart failure, and the increase of plasma levels of ANP in SHR but had no effect on systolic blood pressure, heart weight, and plasma levels of ANP in WKY. In addition, nisoldipine had a therapeutic effect in old SHR with manifest cardiac failure in end-stage hypertension, as evidenced not only by the reduction of blood pressure but also by the reduction of cardiac hypertrophy, of elevated immunoreactive ANP in plasma, and of increased plasma renin activity.

This article has been cited by other articles:

				Y. M Pinto, M. Paul, and D. Ganten Lessons from rat models of hypertension: from Goldblatt to genetic engineering Cardiovasc Res, July 1, 1998; 39(1): 77 - 88. [Abstract] [Full Text] [PDF]